RPA32/RPA2 (Phospho-phospho T21) Conjugated Antibody

Signalway Antibody

Catalog No: #C13390

Package Size: #C13390-AF350 100ul #C13390-AF405 100ul #C13390-AF488 100ul

#C13390-AF555 100ul #C13390-AF594 100ul #C13390-AF647 100ul

#C13390-AF680 100ul #C13390-AF750 100ul #C13390-Biotin 100ul

Orders: order@signalwayantibody.com Support: tech@signalwayantibody.com

Description

Product Name	RPA32/RPA2 (Phospho-phospho T21) Conjugated Antibody
Host Species	Rabbit
Clonality	Monoclonal
Species Reactivity	Hu, Ms, Rt
Immunogen Description	recombinant protein
Conjugates	Biotin AF350 AF405 AF488 AF555 AF594 AF647 AF680 AF750
Other Names	BDNF/NT-3 growth factors receptor antibody gp140trk antibody GP145-TrkB antibody GP145-TrkC antibody
	High affinity nerve growth factor receptor antibody MTC antibody Neurotrophic tyrosine kinase receptor type
	antibody Neurotrophic tyrosine kinase receptor type 2 antibody Neurotrophic tyrosine kinase receptor type 3
	antibody NT-3 growth factor receptor antibody NTRK1 antibody NTRK2 antibody NTRK3 antibody p140-TrkA
	antibody TRK antibody Trk-A antibody Trk-B antibody Trk-C antibody TRK1-transforming tyrosine kinase
	protein antibody TRKA antibody TRKB antibody TrkB tyrosine kinase antibody TRKC antibody TrkC tyrosine
	kinase antibody Tropomyosin-related kinase A antibody Tropomyosin-related kinase B antibody Tyrosine
	kinase receptor A antibody Tyrosine kinase receptor antibody
Accession No.	Swiss-Prot#:P04629
Uniprot	P04629
GeneID	4914;
Excitation Emission	AF350: 346nm/442nm
	AF405: 401nm/421nm
	AF488: 493nm/519nm
	AF555: 555nm/565nm
	AF594: 591nm/614nm
	AF647: 651nm/667nm
	AF680: 679nm/702nm
	AF750: 749nm/775nm
Calculated MW	140
Formulation	0.01M Sodium Phosphate, 0.25M NaCl, pH 7.6, 5mg/ml Bovine Serum Albumin, 0.02% Sodium Azide
Storage	Store at 4°C in dark for 6 months

Application Details

Suggested Dilution:

AF350 conjugated: most applications: 1: 50 - 1: 250 AF405 conjugated: most applications: 1: 50 - 1: 250

AF488 conjugated: most applications: 1: 50 - 1: 250
AF555 conjugated: most applications: 1: 50 - 1: 250
AF594 conjugated: most applications: 1: 50 - 1: 250
AF647 conjugated: most applications: 1: 50 - 1: 250
AF680 conjugated: most applications: 1: 50 - 1: 250
AF750 conjugated: most applications: 1: 50 - 1: 250

Biotin conjugated: working with enzyme-conjugated streptavidin, most applications: 1: 50 - 1: 1,000

Background

The family of Trk receptor tyrosine kinases consists of TrkA, TrkB, and TrkC. While the sequence of these family members is highly conserved, they are activated by different neurotrophins: TrkA by NGF, TrkB by BDNF or NT4, and TrkC by NT3. In the adult nervous system, the Trk receptors regulate synaptic strength and plasticity. TrkA regulates proliferation and is important for development and maturation of the nervous system. Point mutations, deletions, and chromosomal rearrangements (chimeras) cause ligand-independent receptor dimerization and activation of TrkA. TrkA is activated in many malignancies including breast, ovarian, prostate, and thyroid carcinomas. TrkB is overexpressed in tumors such as neuroblastoma, prostate adenocarcinoma and pancreatic ductal adenocarcinoma. In neuroblastomas overexpression of TrkB correlates with unfavorable disease outcome when autocrine loops signaling tumor survival are potentiated by additional overexpression of brain-derived neurotrophic factor (BDNF). An alternatively spliced truncated TrkB isoform lacking the kinase domain is overexpressed in Wilmsoû½oû½ tumors and this isoform may act as a dominant-negative to TrkB signaling. Altered TrkC expression and corresponding gene mutations are seen in various forms of cancer, with increased expression a positive prognostic indicator in patients with medulloblastoma.

Note: This product is for in vitro research use only